Core Viewpoint - Kang En Bei's stock price experienced a decline of 1.06% on July 31, closing at 4.65 yuan, with a trading volume of 367,000 hands and a transaction amount of 171 million yuan [1] Company Overview - Kang En Bei operates in the pharmaceutical manufacturing industry, specifically within the traditional Chinese medicine sector, focusing on drug research, production, and sales [1] - The company's product range includes traditional Chinese medicine preparations, chemical raw materials and preparations, and biological products, indicating a comprehensive pharmaceutical industry chain [1] Recent Developments - On July 31, Kang En Bei announced that its wholly-owned subsidiary, Hangzhou Kang En Bei Pharmaceutical Co., Ltd., received approval from the National Medical Products Administration for the drug registration certificate of Aminocaproic Acid Tablets, which are used to treat various bleeding symptoms caused by hyperfibrinolysis [1] - The research and development investment for this drug was approximately 6.27 million yuan, and it is considered to have passed the consistency evaluation for generic drugs [1] Market Activity - On the same day, the main funds for Kang En Bei saw a net outflow of 1.6435 million yuan, accounting for 0.01% of the circulating market value [1]

证券日报网讯7月31日晚间，康恩贝（600572）发布公告称，近日，公司全资子公司杭州康恩贝制药有 限公司收到国家药品监督管理局核准签发的规格为0.25g的氨甲环酸片《药品注册证书》。 ...

康恩贝（SH 600572，收盘价：4.65元）7月31日晚间发布公告称，近日，浙江康恩贝制药股份有限公司 全资子公司杭州康恩贝制药有限公司收到国家药品监督管理局核准签发的规格为0.25g的氨甲环酸片 《药品注册证书》。 （文章来源：每日经济新闻） 2024年1至12月份，康恩贝的营业收入构成为：制造业(医药工业)占比86.86%，商业销售占比11.77%， 其他业务占比1.37%。 ...

一、药品注册证书的主要内容 药品名称：氨甲环酸片 剂型：片剂 证券简称：康恩贝 证券代码：600572 编号：2025-038 浙江康恩贝制药股份有限公司 关于子公司氨甲环酸片获得药品注册证书的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重大遗漏，并对其 内容的真实性、准确性和完整性承担法律责任。 近日，浙江康恩贝制药股份有限公司（以下简称"公司""本公司"）全资子公司杭 州康恩贝制药有限公司（以下简称"杭州康恩贝"）收到国家药品监督管理局（以下简称 "国家药监局"）核准签发的规格为 0.25g 的氨甲环酸片《药品注册证书》，现将相关情 况公告如下： 规格：0.25g 注册分类：化学药品 4 类 上市许可持有人：杭州康恩贝 批准文号：国药准字 H20255025 证书编号：2025S02376 审批结论：根据《中华人民共和国药品管理法》及有关规定，经审查，本品符合药品 注册的有关要求，批准注册，发给药品注册证书。 二、该药品研发情况 氨甲环酸片的原研厂家为日本第一三共株式会社，其在日本获批上市的氨甲环酸片有 0.25g 规格和 0.5g 规格，其中 0.5g 规格在中国获批上市 ...

Core Viewpoint - Kangnibei (600572.SH) has received approval from the National Medical Products Administration for its subsidiary Hangzhou Kangnibei Pharmaceutical Co., Ltd. to market a 0.25g specification of Tranexamic Acid Tablets [1] Group 1 - The original manufacturer of Tranexamic Acid Tablets is Daiichi Sankyo Co., Ltd. from Japan, which has approved both 0.25g and 0.5g specifications in Japan, with the 0.5g specification already approved for sale in China [1] - Tranexamic Acid Tablets are primarily used for treating various bleeding conditions caused by acute or chronic, localized or systemic primary fibrinolysis, as well as secondary hyperfibrinolytic states due to disseminated intravascular coagulation [1]

氨甲环酸片的原研厂家为日本第一三共株式会社，其在日本获批上市的氨甲环酸片有0.25g规格和0.5g规 格，其中0.5g规格在中国获批上市。氨甲环酸片主要用于急性或慢性、局限性或全身性原发性纤维蛋白 溶解亢进所致的各种出血;弥散性血管内凝血所致的继发性高纤溶状态。 智通财经APP讯，康恩贝(600572.SH)发布公告，近日，公司全资子公司杭州康恩贝制药有限公司("杭州 康恩贝")收到国家药品监督管理局(以下简称"国家药监局")核准签发的规格为0.25g的氨甲环酸片《药品 注册证书》。 ...

康恩贝(600572.SH)公告称，公司全资子公司杭州康恩贝收到国家药监局核准签发的规格为0.25g的氨甲 环酸片《药品注册证书》。该药品主要用于急性或慢性、局限性或全身性原发性纤维蛋白溶解亢进所致 的各种出血；弥散性血管内凝血所致的继发性高纤溶状态。杭州康恩贝于2024年4月递交注册申请并获 受理，近日获得证书。截至目前，杭州康恩贝已投入研发费用约627万元。根据国家相关政策，该药品 视同通过仿制药一致性评价，预计将对公司业绩产生积极影响。 ...

格隆汇7月31日丨康恩贝(600572.SH)公布，全资子公司杭州康恩贝制药有限公司（称"杭州康恩贝"）收 到国家药品监督管理局核准签发的规格为0.25g的氨甲环酸片《药品注册证书》，氨甲环酸片主要用于 急性或慢性、局限性或全身性原发性纤维蛋白溶解亢进所致的各种出血；弥散性血管内凝血所致的继发 性高纤溶状态。 ...

证券简称：康恩贝 证券代码：600572 编号：2025-037 浙江康恩贝制药股份有限公司 关于子公司培哚普利氨氯地平片（Ⅲ） 获得药品注册证书的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重大遗漏，并对其 内容的真实性、准确性和完整性承担法律责任。 注册分类：化学药品 4 类 上市许可持有人：杭州康恩贝 批准文号：国药准字 H20254915 证书编号：2025S02246 审批结论：根据《中华人民共和国药品管理法》及有关规定，经审查，本品符合药品 注册的有关要求，批准注册，发给药品注册证书。 近日，浙江康恩贝制药股份有限公司（以下简称"公司""本公司"）全资子公司杭 州康恩贝制药有限公司（以下简称"杭州康恩贝"）收到国家药品监督管理局（以下简称 "国家药监局"）核准签发的培哚普利氨氯地平片（Ⅲ）《药品注册证书》，现将相关情 况公告如下： 一、药品注册证书的主要内容 药品名称：培哚普利氨氯地平片（Ⅲ） 剂型：片剂 规格：每片含精氨酸培哚普利 10mg、苯磺酸氨氯地平 5mg（按 C₂₀H₂₅N₂O₅Cl 计） 三、其他相关情况 根据国家药监局网站显示，截至本公告日，培哚普利 ...

Buyback Approval and Plan - The board of directors approved a share buyback plan using self-owned funds through centralized bidding on January 23, 2024, with a total fund amount between 200 million yuan and 400 million yuan, and a maximum buyback price of 7 yuan per share [1] Buyback Implementation - The company initiated its first share buyback on January 29, 2024, and completed the buyback by July 21, 2024, acquiring 63.579048 million shares, which is 2.47% of the total share capital at that time. The highest buyback price was 5.00 yuan per share, the lowest was 4.08 yuan, and the average price was 4.72 yuan, with a total expenditure of approximately 299.9241 million yuan [2][3] Use of Funds and Impact - The funds used for the buyback were from the company's own resources and did not significantly impact its daily operations, financial status, or future development. The buyback did not alter the company's control or affect its listing status [3] Shareholder Trading Activity - During the buyback period, company directors, supervisors, and senior management did not trade company shares, except for the controlling shareholder, Zhejiang Pharmaceutical Health Industry Group, which planned to increase its stake by 2% to 4% of the total share capital [3] Change in Buyback Share Purpose - The purpose of the repurchased shares was changed from "for equity incentives" to "for cancellation to reduce registered capital" as approved in board meetings held on April 23 and May 2025 [3] Cancellation of Repurchased Shares - The company announced a notification to creditors regarding the cancellation of repurchased shares, with a creditor declaration period from May 24 to July 7, 2025. No creditors requested early debt repayment or guarantees during this period [5] Post-Cancellation Share Capital Changes - After the cancellation of shares, the total share capital will decrease from 2,585,167,996 shares to 2,521,588,948 shares, reflecting a change in ownership percentages among shareholders [6] Shareholder Ownership Changes - Following the cancellation, the controlling shareholder, Zhejiang Pharmaceutical Health Industry Group, maintained its shareholding at 594,209,740 shares, increasing its ownership percentage from 22.99% to 23.56% [6]